相关实验视频

Updated: Jan 15, 2026

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Automated Preparation of [⁶⁸Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

基法酸,一种选择性P2X3受体对手,可能改善与癌症相关的高性:一个案例报告

Satoshi Murakami¹, Kazutaka Yamagishi², Akira Kitani³

¹Department of Palliative Medicine, Seirei Sakura Citizen Hospital, Chiba, Japan.

Journal of palliative medicine

|October 7, 2025

概括

用于咳的Gefapixant酸盐出乎意料地改善了一名癌症患者的严重味觉障碍 (高热血症). 这表明对管理味觉障碍和改善类似情况下的口服摄入有潜在的益处.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
胃肠病学胃肠病学

背景情况:

癌症患者经常患有味觉障碍,严重影响他们的生活质量.
格法皮克桑酸盐是一种P2X纯感受体3受体对手,是一种抗咳药物,已知具有与味道相关的副作用.
过高,一种异常的味觉增强,可以导致癌症患者的食欲丧失.

研究的目的:

报告患有癌症患者的临床过程,经历过高地质症.
调查fefapixant酸盐对癌症患者难治性咳和先前存在的高的作用.
评估fefapixant酸盐在治疗瘤学上的味觉障碍方面的潜力.

主要方法:

一个85岁的女性患有肺癌和恶性肺炎的案例研究.
在停止侵袭性癌症治疗后,为耐火性咳服用gefaixant酸盐.
监测患者报告的关于味道,食欲和口服摄入的结果.

主要成果:

患者经历了显著的改善,在hypergeusia和口服摄入后fefapixant酸盐的管理.
对口味和口服摄入的积极影响持续了3周.
在治疗期间,耐火性咳也得到了控制.

结论:

酸格法皮克桑 (Gefapixant citrate) 显示出改善高凝血症的潜力,并支持癌症患者的口服摄入,患有难治性咳.
这一发现表明,fefapixant酸盐在治疗瘤学上的味觉障碍方面可能具有治疗作用.
建议谨慎使用,因为在癌症缓解症和潜在的与味道相关的不良影响中有效性有限.

关键词:

作为P2X3受体对抗剂.癌症缓冲症癌症缓冲症这是一种 gefapixant 酸盐.超高质地症是什么?味觉障碍味觉障碍味觉障碍味觉障碍

更多相关视频

An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use

An Automated Radiosynthesis of [⁶⁸Ga]Ga-FAPI-46 for Routine Clinical Use

Published on: May 24, 2024

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Published on: January 4, 2012

相关概念视频

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...